Summary of Demographics and Baseline Variables
| Variable . | . | RheothRx . | Placebo . | Total . |
|---|---|---|---|---|
| . | . | (n = 28) . | (n = 22) . | . |
| Age (yr) | Median | 25.0 | 26.5 | |
| Range | 19-42 | 15-55 | ||
| Sex | Female | 13 (46%) | 12 (55%) | |
| Male | 15 (54%) | 10 (45%) | ||
| Weight (kg) | Median | 60.3 | 63.0 | |
| Range | 40.0-80.0 | 52.0-103.4 | ||
| Sickle cell diseases class | HbSS | 25 (89%) | 21 (96%) | |
| HbSB°-thal | 2 (7%) | 1 (4%) | ||
| HbSC | 1 (4%) | 0 (0%) | ||
| Hours from onset to start of study drug infusion | Median | 17.1 | 16.0 | |
| Range | 5.4-65.3 | 8.5-48.5 | ||
| Baseline pain score | Moderate | 17 (61%) | 8 (36%) | |
| Severe | 11 (39%) | 14 (64%) | ||
| Accrual Rate by Center | 1 | 2 | 2 | 4 (8%) |
| 3 | 8 | 5 | 13 (26%) | |
| 4 | 8 | 6 | 14 (28%) | |
| 5 | 6 | 4 | 10 (20%) | |
| 6 | 4 | 5 | 9 (18%) |
| Variable . | . | RheothRx . | Placebo . | Total . |
|---|---|---|---|---|
| . | . | (n = 28) . | (n = 22) . | . |
| Age (yr) | Median | 25.0 | 26.5 | |
| Range | 19-42 | 15-55 | ||
| Sex | Female | 13 (46%) | 12 (55%) | |
| Male | 15 (54%) | 10 (45%) | ||
| Weight (kg) | Median | 60.3 | 63.0 | |
| Range | 40.0-80.0 | 52.0-103.4 | ||
| Sickle cell diseases class | HbSS | 25 (89%) | 21 (96%) | |
| HbSB°-thal | 2 (7%) | 1 (4%) | ||
| HbSC | 1 (4%) | 0 (0%) | ||
| Hours from onset to start of study drug infusion | Median | 17.1 | 16.0 | |
| Range | 5.4-65.3 | 8.5-48.5 | ||
| Baseline pain score | Moderate | 17 (61%) | 8 (36%) | |
| Severe | 11 (39%) | 14 (64%) | ||
| Accrual Rate by Center | 1 | 2 | 2 | 4 (8%) |
| 3 | 8 | 5 | 13 (26%) | |
| 4 | 8 | 6 | 14 (28%) | |
| 5 | 6 | 4 | 10 (20%) | |
| 6 | 4 | 5 | 9 (18%) |